Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C03 DIURETICS
C03X OTHER DIURETICS
C03XA Vasopressin antagonists
C03XA01 Tolvaptan
D01213 Tolvaptan (JP18/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Electrolytes/Minerals/Metals/Vitamins
Electrolyte/Mineral/Metal Modifiers
Tolvaptan
D01213 Tolvaptan (JP18/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
213 Diuretics
2139 Others
D01213 Tolvaptan (JP18/USAN/INN)
24 Hormones
249 Miscellaneous
2499 Others
D01213 Tolvaptan (JP18/USAN/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01506 Arginine vasopressin receptor 2 (AVPR2) antagonist
DG03074 Tolvaptan
D01213 Tolvaptan
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D01213 Tolvaptan
Transporter substrate
DG01665 ABCB1 substrate
D01213 Tolvaptan
Transporter inhibitor
DG01622 ABCB1 inhibitor
D01213 Tolvaptan
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Vasopressin
AVPR2
D01213 Tolvaptan (JP18/USAN/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01213 Tolvaptan
D01213 Tolvaptan tablets
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01213
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01213
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01213
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01213
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01213
Drug transporters
D01213
Drug groups [BR:br08330]
Cardiovascular agent
DG01506 Arginine vasopressin receptor 2 (AVPR2) antagonist
DG03074 Tolvaptan